Cargando…

Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement

The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live atte...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalaj‐Hedayati, Atin, Chua, Caroline Lin Lin, Smooker, Peter, Lee, Khai Wooi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928032/
https://www.ncbi.nlm.nih.gov/pubmed/31774251
http://dx.doi.org/10.1111/irv.12697
_version_ 1783482393879904256
author Khalaj‐Hedayati, Atin
Chua, Caroline Lin Lin
Smooker, Peter
Lee, Khai Wooi
author_facet Khalaj‐Hedayati, Atin
Chua, Caroline Lin Lin
Smooker, Peter
Lee, Khai Wooi
author_sort Khalaj‐Hedayati, Atin
collection PubMed
description The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen‐presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen‐presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.
format Online
Article
Text
id pubmed-6928032
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69280322020-01-01 Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement Khalaj‐Hedayati, Atin Chua, Caroline Lin Lin Smooker, Peter Lee, Khai Wooi Influenza Other Respir Viruses Formal Systematic Review (Commissioned or Non‐commissioned) The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen‐presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen‐presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses. John Wiley and Sons Inc. 2019-11-27 2020-01 /pmc/articles/PMC6928032/ /pubmed/31774251 http://dx.doi.org/10.1111/irv.12697 Text en © 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Formal Systematic Review (Commissioned or Non‐commissioned)
Khalaj‐Hedayati, Atin
Chua, Caroline Lin Lin
Smooker, Peter
Lee, Khai Wooi
Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
title Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
title_full Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
title_fullStr Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
title_full_unstemmed Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
title_short Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
title_sort nanoparticles in influenza subunit vaccine development: immunogenicity enhancement
topic Formal Systematic Review (Commissioned or Non‐commissioned)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928032/
https://www.ncbi.nlm.nih.gov/pubmed/31774251
http://dx.doi.org/10.1111/irv.12697
work_keys_str_mv AT khalajhedayatiatin nanoparticlesininfluenzasubunitvaccinedevelopmentimmunogenicityenhancement
AT chuacarolinelinlin nanoparticlesininfluenzasubunitvaccinedevelopmentimmunogenicityenhancement
AT smookerpeter nanoparticlesininfluenzasubunitvaccinedevelopmentimmunogenicityenhancement
AT leekhaiwooi nanoparticlesininfluenzasubunitvaccinedevelopmentimmunogenicityenhancement